A novel series of 3-(4-fluorophenyl)-4,5-dihydro-5-(3,4,5-trimethoxy/4-nitro phenyl)-N-(substituted-phenyl)pyrazole-1-carboxamide analogues 4a-n was synthesized in two steps from 4-fluoroacetophenone. The pyrazoline analogues were evaluated for cytotoxicity against two breast cancer cell lines (MCF-7 and MBA-MD-231) by the sulforhodamine B (SRB) assay.showed the most promising cytotoxicity among the series, with GI 50 <0.1 and 45.8 μM against the cancer cell lines, MCF-7 and MDA-MB-231, respectively. The anticancer activity of 4b was found to be comparable to that of the standard drug adriamycin (GI 50 <0.1) against the MCF-7 cancer cell line. Structure activity relationships (SAR) are also considered.
Key words anticancer agents, breast cancer cell lines, MCF-7, MDA-MB-231, SRB assay, pyrazolinesIn 2015, nearly 8.8 million cancer related deaths were reported. In India, every year over 0.7 million new cancer patients are registered and 0.5 million cancer related death are reported, 1,2 and it is expected that new cases of cancer will amount to 19.3 million per annum worldwide by
2025.3 Chemotherapy is an important approach to cancer treatment, but it has drawbacks of toxicity, resistance, and genotoxicity. 4 Today, we need to focus on drug discovery programmes to develop effective and safer anticancer agents for cancer treatment.Five-membered pyrazoline rings have received much attention because of their diverse biological potential. Some of the pyrazoline incorporated compounds that have promising biological activities are shown in Figure 1. Pyrazoloacridine (I) is a new anticancer agent in Phase II clinical trial. 5-7 3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1) (II) is a hypoxia-inducible factor (HIF)-1 inhibitor. 8,9 Axitinib (AG013736) (III) is an endothelial growth factor receptor (VEGFR) inhibitor in clinical practice.10,11 4-(4-Chlorophenyl)-2-(3-(3,4-dimethylphenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazole (IV) is an EGFR TK inhibitor (IC 50 = 0.06 μM).12 5-Bromo-3-{2-[5-(4-methoxyphenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl]-4-oxo-4,5-dihydro-1,3-thiazol-5-ylidene}-2,3-dihydro-1H-indol-2-one (V) is a potent anticancer agent with promising activity against HOP-92 (GI 50 < 0.01 μM), HCT-116 (GI 50 = 0.018 μM), SNB-75 (GI 50 = 0.0159 μM), RXF 393 (GI 50 = 0.0197 μM), and NCI/ADR-RES (GI 50 = 0.0169 μM).13 3-Benzofuran-2-yl-5-(4-dimethylaminonaphthalen-1-yl)-4,5-dihydropyrazole-1-carbothioic acid amide (VI) was found to